Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
18 November 2020 | Story Thabo Kessah | Photo Thabo Kessah
Prof Pearl Sithole acknowledged the role played by the Afromontane Research Unit in securing mountain-to-mountain research funding from the US Embassy and Consulates in SA.

“This launch is an opportunity to reflect on the strategic significance of the partnership between our two universities and the long-standing relationship that academics at the two institutions have enjoyed.” 

These were the words of appreciation from the University of the Free State Vice-Rector: Research, Innovation and Internationalisation, Prof Corli Witthuhn, during the virtual launch of the Mountain-to-Mountain collaboration project between the University of the Free State and the Appalachian State University in the United States held on 10 November 2020. The R8 million project is funded by the US Embassy and Consulates in South Africa and will run over two academic years.

Prof Witthuhn also stated that the project would further strengthen the UFS strategy for internationalisation. “This collaboration has grown organically in the last decade to become one of the UFS flagships in international collaborations. With the support of this grant from the US Embassy and Consulates in South Africa, this long-standing and sustainable collaboration will be further strengthened,” she added.

New master’s programmes

In providing context to the Qwaqwa Campus’ research footprint, Campus Vice-Principal: Academic and Research, Prof Pearl Sithole, acknowledged the role played by the Afromontane Research Unit (ARU) under the leadership of its Director, Dr Ralph Clark, as well as all the faculties.

“In the Humanities, a lot is coming regarding the socio-ecosystems of the mountains. And in Education and Economic and Management Sciences, the scholarship of teaching and learning is promoted through blended skills, especially during this time of the pandemic. In the Natural and Agricultural Sciences, climate monitoring is one of the projects that has brought vibrancy to our campus,” she said.

Appalachian State University’s Associate Vice-Chancellor for International Education and Development, Prof Jesse Lutabingwa, mentioned that the collaboration would, among others, develop and offer a multi-disciplinary master’s degree in Mountain Studies on the Qwaqwa Campus, which will initially enrol seven to ten students. “In the subsequent years, we plan to increase this number to 15-20 students. We will also develop and offer a Community Development master’s degree with 10-12 students and up to 25 in subsequent years.”

Black women academics

Prof Lutabingwa, who is also the Project Director, revealed that doctoral students who are currently part of the University Staff Doctoral Project (USDP), will conduct at least three research projects focusing on social entrepreneurship, substance abuse, and rural transport monitoring in the Maloti-Drakensberg Mountains. “Also key to this collaboration is the leadership mentorship programme for black women academics who will at the end of the project produce three to five research papers,” Prof Lutabingwa added.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept